Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data

被引：1
|
作者：
Skrobo, D. [1 ]
Walsh, N. [2 ]
Quinn, C. [3 ]
Walshe, J. [4 ]
Smyth, L. M. [5 ]
Gullo, G. [4 ]
Crown, J. P. [4 ]
机构：
[1] St Vincents Univ Hosp, Dept Oncol, Dublin, Ireland
[2] Natl Inst Cellular Biotechnol, Sch Biotechnol, Dublin, Ireland
[3] St Vincents Univ Hosp, Pathol, Dublin, Ireland
[4] St Vincents Univ Hosp, Med Oncol, Dublin, Ireland
[5] St Vincents Univ Hosp, Dublin, Ireland
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.273
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [31] Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases
    Artac, Mehmet
    Koral, Lokman
    Toy, Hatice
    Guler, Tunc
    Boruban, Melih C.
    Altundag, Kadri
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (02) : 141 - 145
  • [32] Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations
    Harbeck, Nadia
    Wuerstlein, Rachel
    [J]. DRUGS, 2013, 73 (15) : 1665 - 1680
  • [33] Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
    Gong, Inna Y.
    Yan, Andrew T.
    Earle, Craig C.
    Trudeau, Maureen E.
    Eisen, Andrea
    Chan, Kelvin K. W.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 155 - 165
  • [34] Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
    Inna Y. Gong
    Andrew T. Yan
    Craig C. Earle
    Maureen E. Trudeau
    Andrea Eisen
    Kelvin K. W. Chan
    [J]. Breast Cancer Research and Treatment, 2020, 181 : 155 - 165
  • [35] Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations
    Nadia Harbeck
    Rachel Wuerstlein
    [J]. Drugs, 2013, 73 : 1665 - 1680
  • [36] The perspective of anti-HER2 therapy for HER2 positive breast cancer
    Iwata, Hiroji
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [37] Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
    Sabine Schmid
    Dirk Klingbiel
    Stefan Aebi
    Aron Goldhirsch
    Christoph Mamot
    Elisabetta Munzone
    Franco Nolè
    Christian Oehlschlegel
    Olivia Pagani
    Bernhard Pestalozzi
    Christoph Rochlitz
    Beat Thürlimann
    Roger von Moos
    Patrik Weder
    Khalil Zaman
    Thomas Ruhstaller
    [J]. BMC Cancer, 19
  • [38] Long-term responders to trastuzumab monotherapy in first-line HER-2+advanced breast cancer: characteristics and survival data
    Schmid, Sabine
    Klingbiel, Dirk
    Aebi, Stefan
    Goldhirsch, Aron
    Mamot, Christoph
    Munzone, Elisabetta
    Nole, Franco
    Oehlschlegel, Christian
    Pagani, Olivia
    Pestalozzi, Bernhard
    Rochlitz, Christoph
    Thuerlimann, Beat
    von Moos, Roger
    Weder, Patrik
    Zaman, Khalil
    Ruhstaller, Thomas
    [J]. BMC CANCER, 2019, 19 (01)
  • [39] Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
    Kyle Dunton
    Gerard Vondeling
    Elizabeth Hancock
    Margaret Petrou
    Oliver Burn
    Abby Paine
    [J]. Targeted Oncology, 2022, 17 : 655 - 663
  • [40] Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
    Dunton, Kyle
    Vondeling, Gerard
    Hancock, Elizabeth
    Petrou, Margaret
    Burn, Oliver
    Paine, Abby
    [J]. TARGETED ONCOLOGY, 2022, 17 (06) : 655 - 663
12345